Hilltop Park Associates’s Anthera Pharmaceuticals, Inc. ANTH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q3
$315K Buy
12,500
+3,125
+33% +$78.8K 0.58% 29
2016
Q2
$232K Buy
9,375
+1,250
+15% +$35.3K 0.97% 13
2016
Q1
$235K Sell
8,125
-10,625
-57% -$288K 0.52% 24
2015
Q4
$696K Buy
18,750
+4,062
+28% +$179K 2.32% 14
2015
Q3
$716K Sell
14,688
-312
-2% -$21.8K 10.78% 2
2015
Q2
$1.03M Sell
15,000
-2,013
-12% -$93.2K 2.05% 20
2015
Q1
$608K Buy
+17,013
New +$504K 1.11% 23

Other funds holding ANTH

Hilltop Park Associates's ANTH Position: Q3 2016 in Review

Hilltop Park Associates increased its Anthera Pharmaceuticals, Inc. (ANTH) stake by 33% in Q3 2016, buying an estimated $78.8K and bringing the position to 12,500 shares worth $315K. The position accounts for 0.58% of the portfolio, ranked #29.

Hilltop Park Associates first reported a position in ANTH in Q1 2015 and has held it in 7 quarters since. The position peaked at $1.03M in Q2 2015. 72 funds tracked by Wall St. Rank hold ANTH as of Q3 2016.

  • Hilltop Park Associates held 12,500 shares of Anthera Pharmaceuticals, Inc. worth $315K as of Q3 2016.
  • Hilltop Park Associates bought 3,125 Anthera Pharmaceuticals, Inc. shares in Q3 2016, an estimated $78.8K.
  • Anthera Pharmaceuticals, Inc. made up 0.58% of Hilltop Park Associates's portfolio in Q3 2016, its #29 holding.
  • Hilltop Park Associates first reported a position in Anthera Pharmaceuticals, Inc. in Q1 2015 and has held it in 7 quarters since.
  • Hilltop Park Associates's Anthera Pharmaceuticals, Inc. position peaked at $1.03M in Q2 2015.
  • 72 funds tracked by Wall St. Rank held Anthera Pharmaceuticals, Inc. as of Q3 2016.

Based on Hilltop Park Associates's 13F filing for Q3 2016, filed 10 Nov 2016.